AU2002228805A1 - Antisense modulation of damage-specific dna binding protein 2, p48 expression - Google Patents
Antisense modulation of damage-specific dna binding protein 2, p48 expressionInfo
- Publication number
- AU2002228805A1 AU2002228805A1 AU2002228805A AU2880502A AU2002228805A1 AU 2002228805 A1 AU2002228805 A1 AU 2002228805A1 AU 2002228805 A AU2002228805 A AU 2002228805A AU 2880502 A AU2880502 A AU 2880502A AU 2002228805 A1 AU2002228805 A1 AU 2002228805A1
- Authority
- AU
- Australia
- Prior art keywords
- expression
- damage
- binding protein
- dna binding
- specific dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102100021122 DNA damage-binding protein 2 Human genes 0.000 title 1
- 101710137105 DNA damage-binding protein 2 Proteins 0.000 title 1
- 102100037878 Pancreas transcription factor 1 subunit alpha Human genes 0.000 title 1
- 230000000692 anti-sense effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09732199 | 2000-12-06 | ||
US09/732,199 US6379960B1 (en) | 2000-12-06 | 2000-12-06 | Antisense modulation of damage-specific DNA binding protein 2, p48 expression |
PCT/US2001/046480 WO2002046473A1 (en) | 2000-12-06 | 2001-12-04 | Antisense modulation of damage-specific dna binding protein 2, p48 expression |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002228805A1 true AU2002228805A1 (en) | 2002-06-18 |
Family
ID=24942580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002228805A Abandoned AU2002228805A1 (en) | 2000-12-06 | 2001-12-04 | Antisense modulation of damage-specific dna binding protein 2, p48 expression |
Country Status (3)
Country | Link |
---|---|
US (1) | US6379960B1 (en) |
AU (1) | AU2002228805A1 (en) |
WO (1) | WO2002046473A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030105037A1 (en) * | 2001-10-06 | 2003-06-05 | Isis Pharmaceuticals Inc. | Antisense modulation of inhibitor-kappa B kinase-gamma expression |
US8119159B2 (en) * | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US20070148228A1 (en) * | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
WO2002092616A1 (en) * | 2001-05-11 | 2002-11-21 | Orasense, Ltd. | Antisense permeation enhancers |
EP2007397B1 (en) * | 2006-04-07 | 2013-07-24 | Merrion Research III Limited | Solid oral dosage form containing an enhancer |
EP2040731A4 (en) * | 2006-06-09 | 2010-05-19 | Merrion Res Iii Ltd | Solid oral dosage form containing an enhancer |
WO2009023615A1 (en) | 2007-08-10 | 2009-02-19 | Trustees Of Tufts College | Tubular silk compositions and methods of use thereof |
US8999383B2 (en) * | 2008-05-07 | 2015-04-07 | Merrion Research Iii Limited | Compositions of GnRH related compounds and processes of preparation |
TWI480286B (en) * | 2009-02-25 | 2015-04-11 | Merrion Res Iii Ltd | Composition and drug delivery of bisphosphonates |
US20110182985A1 (en) * | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
US9089484B2 (en) * | 2010-03-26 | 2015-07-28 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor Xa inhibitors for oral administration |
KR20140026354A (en) | 2011-01-07 | 2014-03-05 | 메리온 리서치 Ⅲ 리미티드 | Pharmaceutical compositions of iron for oral administration |
JP7211704B2 (en) | 2015-01-29 | 2023-01-24 | ノヴォ ノルディスク アー/エス | A tablet containing a GLP-1 agonist and an enteric coating |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
US5951455A (en) * | 1998-12-04 | 1999-09-14 | Isis Pharmaceuticals, Inc. | Antisense modulation of G-alpha-11 expression |
-
2000
- 2000-12-06 US US09/732,199 patent/US6379960B1/en not_active Expired - Lifetime
-
2001
- 2001-12-04 WO PCT/US2001/046480 patent/WO2002046473A1/en not_active Application Discontinuation
- 2001-12-04 AU AU2002228805A patent/AU2002228805A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002046473A1 (en) | 2002-06-13 |
US6379960B1 (en) | 2002-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU6508499A (en) | Antisense modulation of microtubule-associated protein 4 expression | |
AU4193700A (en) | Antisense oligonucleotide compositions and methods for the modulation of jnk proteins | |
AU7097400A (en) | Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof | |
AU4065000A (en) | Antisense modulation of p38 mitogen activated protein kinase expression | |
AU4498500A (en) | Phytyl/prenyltransferase nucleic acids, polypeptides and uses thereof | |
AU2002228805A1 (en) | Antisense modulation of damage-specific dna binding protein 2, p48 expression | |
AU1221201A (en) | Antisense modulation of y-box binding protein 1 expression | |
AU2002218269A1 (en) | Proteins and dna sequences underlying these proteins used for treating inflammations | |
AU2002217929A1 (en) | Modulation of gene expression using insulator binding proteins | |
AU2001257220A1 (en) | Antisense modulation of inhibitor of dna binding-1 expression | |
AU5245900A (en) | Novel protein and dna thereof | |
AU2001274566A1 (en) | Novel protein and dna thereof | |
AU2001296413A1 (en) | Oligonucleotide modulation of her-1 expression | |
AU3556800A (en) | Expression of dna or proteins in (c. elegans) | |
AU4684099A (en) | Oligonucleotides for enhanced modulation of protein kinase expression | |
AU2001290872A1 (en) | Isolated human kinase proteins, nucleic acid molecules and uses thereof | |
AU2001292790A1 (en) | Antisense modulation of syntaxin 4 interacting protein expression | |
AU2002241586A1 (en) | Antisense modulation of damage-specific dna binding protein 1, p127 expression | |
AU8229901A (en) | Genes and proteins, and their uses | |
AU2002245190A1 (en) | Antisense modulation of integrin beta 4 binding protein expression | |
AU2001271276A1 (en) | Isolated human aminotransferase proteins, nucleic acid molecules encoding human aminotransferase proteins, and uses thereof | |
AU1320600A (en) | Human rna binding proteins | |
AU2225401A (en) | Novel protein and dna thereof | |
AU2001259240A1 (en) | Novel stmst protein and nucleic acid mocecules and uses therefor | |
AU2001259169A1 (en) | Cesert genes, proteins, and modulatory compounds |